Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZAR: first-line Dato-DXd + durvalumab + carboplatin versus pembrolizumab + platinum chemotherapy in advanced NSCLC without actionable driver alterations
CTR20230817Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, durvalumab, carboplatin, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2023; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230817.